UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000052464 |
|---|---|
| Receipt number | R000059872 |
| Scientific Title | A study to evaluate the effects of the test food on improving fatigue sensation, cognitive function and sleep quality |
| Date of disclosure of the study information | 2023/11/01 |
| Last modified on | 2023/10/11 15:43:10 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A study to evaluate the effects of the test food on improving fatigue sensation, cognitive function and sleep quality
Acronym
A study to evaluate the effects of the test food on improving fatigue sensation, cognitive function and sleep quality
Scientific Title
A study to evaluate the effects of the test food on improving fatigue sensation, cognitive function and sleep quality
Scientific Title:Acronym
A study to evaluate the effects of the test food on improving fatigue sensation, cognitive function and sleep quality
Region
| Japan |
Condition
Condition
Healthy volunteers
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To examine the effects of the test food on improving fatigue sensation, cognitive function and sleep quality
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
VAS (fatigue sensation)
Key secondary outcomes
VAS (sleepiness, motivation, concentration), Chalder fatigue scale, POMS2 Japanese version, autonomic nervous function, blood analysis (adrenalin, noradrenalin, dopamine, d-ROMs, BAP), saliva analysis (HHV-6, HHV-7), cognitive function test, OSA sleep inventory MA version, The St. Mary's Hospital sleep questionnaire, objective sleep evaluation
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Intake of test food for 4 weeks
Interventions/Control_2
Intake of placebo for 4 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1) Males and females whose age of 20 years or more and less than 65 years
2) Subjects having fatigue sensation in daily life
3) Subjects who having complaints regarding daily sleep
4) Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the study and being able to personally sign a written informed consent
Key exclusion criteria
1) Subjects receiving a medical treatment for serious cardio-vascular, hepatic, renal, respiratory, endocrine or metabolic disorders or having a medical history of these disorders
2) Subjects drinking a lot (Subjects whose pure alcohol intake per day is 60 g or more)
3) Subjects having the possibility of developing allergic symptoms by the test food
4) Subjects whose lifestyles are irregular because of night shift or others
5) Subjects waking up for urination 2 times or more during nocturnal sleep
6) Subjects living with their infants less than 1 year old
7) Subjects sleeping with others in a bedroom
8) Subjects taking regularly medicines and quasi-drugs having the effects on fatigue sensation, cognitive function and sleep quality
9) Subjects taking regularly Food with Functional Claims having the effects on fatigue sensation, cognitive function and sleep quality
10) Subjects having blood sample of 200 ml or more taken within 1 month, or 400 ml or more within 3 months prior to the start of the present study (e.g. donated blood)
11)Subjects who are pregnant or lactating, or intending to become pregnant during the study
12) Subjects who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study
13) Subjects deemed unsuitable by the investigator
Target sample size
48
Research contact person
Name of lead principal investigator
| 1st name | Tadakazu |
| Middle name | |
| Last name | Takigami |
Organization
Japan Preventive Medicine Inc.
Division name
Research and Development
Zip code
5600082
Address
Senri Life Science Center 14F, 1-4-2, Shinsenri-higashimachi, Toyonaka, Osaka
TEL
06-6831-3383
takigami_tadakazu@soiken.com
Public contact
Name of contact person
| 1st name | Tadakazu |
| Middle name | |
| Last name | Takigami |
Organization
Japan Preventive Medicine Inc.
Division name
Research and Development
Zip code
5600082
Address
Senri Life Science Center 14F, 1-4-2, Shinsenri-higashimachi, Toyonaka, Osaka
TEL
06-6831-3383
Homepage URL
takigami_tadakazu@soiken.com
Sponsor or person
Institute
Japan Preventive Medicine Inc.
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
IRB of Fukuda Clinic
Address
Shin-Osaka brick building 2F, 1-6- 1 Miyahara, Yodogawa, Osaka, Os aka
Tel
06-6398-0203
fukudaclinicIRB@gmail.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
医療法人弘正会ふくだ内科クリニック（大阪府）
Other administrative information
Date of disclosure of the study information
| 2023 | Year | 11 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2023 | Year | 08 | Month | 19 | Day |
Date of IRB
Anticipated trial start date
| 2023 | Year | 11 | Month | 05 | Day |
Last follow-up date
| 2023 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2023 | Year | 10 | Month | 11 | Day |
Last modified on
| 2023 | Year | 10 | Month | 11 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059872
